National Bowel Cancer Screening Program Policy Framework Phase Four (2015-2020)

Objectives

Phase Four of Australia’s National Bowel Cancer Screening Program, covering 2015–2020, aims to reduce bowel cancer incidence, illness and mortality through early detection of cancers and pre-cancerous lesions, when treatment is most effective.[1][2]It provides phased implementation of free, population-based biennial immunochemical faecal occult blood test screening for eligible people aged 50 to 74 years, with full biennial coverage intended by 2020.[3][4][5]The programme is designed to align with the Australian Population Based Screening Framework, national clinical guidance and evidence on effective, equitable and cost-effective screening.[4][6][7]

• Increase participation and equitable access, particularly for Aboriginal and Torres Strait Islander people, culturally and linguistically diverse communities, rural and remote populations, people with low literacy, and other underserved groups.[6][8][9]
• Detect abnormalities before cancer develops and ensure timely, appropriate, safe and high-quality diagnostic assessment, principally through colonoscopy after a positive test.[4][6][10]
• Maximise screening benefits and minimise harms through informed choice, risk communication, quality assurance and safe follow-up care.[6][11][7]
• Strengthen colonoscopy availability, consistency and quality as screening expansion increases demand, projected to rise from around 20,000 to more than 100,000 procedures annually over five years.[11][12]
• Collect and analyse data to assess participation, pathway performance, outcomes, equity, effectiveness and continuous quality improvement.[6][13][14]
• Support prevention by addressing modifiable bowel cancer risk factors, including smoking, obesity, alcohol consumption, low fibre intake, physical inactivity, and red and processed meat consumption.[15]

Implementation

The programme uses a nationally coordinated but jointly delivered model: the Australian Government Department of Health leads policy, implementation, expenditure, contracting, communications and national infrastructure, while state and territory governments coordinate local services and usual care after positive screening results.[16][17]Screening invitations, test processing, participant follow-up, clinical assessment and treatment are connected through a register-based pathway, contracted providers, primary care and public and private diagnostic services.[10][18][9]Governance is supported by clinical and delivery advisory groups, intergovernmental committees and formal approval processes for major policy changes.[4][16][13]

• Identify eligible people through Medicare and Department of Veterans’ Affairs data; issue pre-invitations, mailed test kits and reminders; permit opt-out or deferral; and use seasonal hot-zone arrangements where high temperatures could affect test performance.[5][10][9]
• Provide iFOBT kits through a contracted pathology provider, communicate results to participants, nominated general practitioners and the Register, and manage positive results through usual care, including clinically indicated colonoscopy and histopathology.[10][18][9]
• Support positive-test follow-up through state and territory Participant Follow-up Function officers, Register reminders and telephone contact where required activities are not recorded.[10][19][20]This function is directly funded through a multilateral National Partnership Agreement under the Federal Financial Relations Framework.[19]
• Transition from the National Bowel Cancer Screening Register to the National Cancer Screening Register in 2018 to improve information capture, reporting, participant and clinician access, and clinical decision-making.[19]Protect personal information under the Privacy Act 2008, Australian Privacy Principles and National Cancer Screening Register Act 2016.[19]
• Engage general practitioners, nurses, gastroenterologists, colonoscopists, surgeons, pathologists and Primary Health Networks to encourage participation, assess positive results, arrange referrals, provide appropriate care and report relevant data.[17][21]
• Implement targeted access measures, including the National Indigenous Bowel Screening Pilot in selected Indigenous primary health care services, where staff directly offer kits and follow-up support to eligible clients.[8]
• Apply a Quality Framework across Commonwealth screening functions and state and territory usual-care responsibilities, supplemented by standards, accreditation, re-certification, training, minimum reporting and a proposed national safety and quality model for colonoscopy.[22][12]
• Monitor performance indicators covering participation, positivity, diagnostic assessment, timeliness, detection, predictive value, interval cancers and outcomes; use Australian Institute of Health and Welfare annual monitoring reports and six-monthly operational reports to inform improvement.[13][14]
• Undertake structured and consultative reviews, including planned five-yearly reviews where feasible, assessment of emerging technologies, and additional reviews prompted by evidence, quality monitoring, research or advisory bodies.[14][23]
• Fund expansion through Australian Government support, including an additional 95.9 million Australian dollars over four years announced in the 2014–15 Budget to accelerate biennial screening by 2020.[9]The supplied material does not provide a total Phase Four budget or detailed funding-gap analysis.[9]

Monitoring & Evaluation

Phase Four uses a whole-pathway monitoring, evaluation and quality-improvement system to assess participation, screening, diagnostic assessment, cancer outcomes, equity, safety and programme effectiveness.[2][14][24]Monitoring is intended to support continuous improvement as biennial screening is progressively implemented for eligible people aged 50 to 74 years.[4][14]

• Measure performance through indicators covering participation, iFOBT positivity, diagnostic assessment, timeliness, adenoma and colorectal cancer detection, predictive value, interval cancers and outcomes.[14]
• Monitor iFOBT positivity within an expected range of 4 to 10 per cent, reflecting the anticipated higher positivity among newly included older cohorts; the Australian Institute of Health and Welfare and Department of Health monitor this through a performance indicator.[5]
• Pilot statistical process control rules to identify material changes in positivity rates requiring investigation, and review rates with advisory groups and the Australian Institute of Health and Welfare as additional age cohorts are introduced.[5]
• Report the performance indicators endorsed in 2014 through annual Australian Institute of Health and Welfare monitoring reports and six-monthly operational reports to the Department of Health and jurisdictional programme managers.[13]
• Collect invitation, reminder, referral, follow-up, procedure, diagnosis and outcome data through the Program Register and, from 2018, the National Cancer Screening Register.[10][19][20]
• Check follow-up after positive results at defined intervals, using Register records, reminder letters and telephone contact where activity has not been recorded.[20]
• Strengthen reporting of colonoscopy adverse outcomes, as incomplete reporting may understate the frequency of complications among participants.[11]
• Use quality audits of contracted providers, a Quality Framework, colonoscopy quality projects, accreditation and minimum reporting systems to support safety and accountability.[16][12]
• Assess performance data for quality, effectiveness, equity, accountability and service planning, while recognising that voluntary, manual clinician reporting has created data gaps.[13]
• Protect Register information under privacy legislation and the National Cancer Screening Register Act 2016, which restricts unauthorised use and disclosure and requires notification to the Information and Privacy Commissioner after a data breach.[19]
• Develop baseline targets and trend expectations for indicators in consultation with advisory groups and the Australian Institute of Health and Welfare; pathological stage distribution and hospital-admission adverse events remain aspirational indicators because data are unavailable.[14]
• Conduct structured, consultative reviews, including regular five-yearly reviews where feasible, and consider further reviews in response to evidence, technology developments, quality monitoring or research.[23]
• Assess effectiveness, cost-effectiveness, governance and the programme model through planned evaluation activity, including the 2017–18 Phase Three evaluation.[24]

Available outcome evidence indicates that programme invitees had a 15 per cent lower risk of bowel cancer death than non-invitees, while cancers detected through the programme were more likely to be diagnosed at an earlier stage.[15][25]The supplied material does not provide final Phase Four evaluation findings, a complete set of indicator targets, or a universal reporting timetable for all pathway measures.[14][8]

Costing & Financing

Programme financing combines Australian Government budget commitments, Commonwealth support for screening and follow-up activities, intergovernmental funding for state and territory services, Medicare support for eligible private care, and limited participant-paid options outside the national programme.[16][17][9][26]The document identifies costs and cost-effectiveness as central considerations but provides limited detailed budget information.[14][25]

• Commit an additional 95.9 million Australian dollars over four years in the 2014–15 Budget to accelerate biennial screening for eligible people aged 50 to 74 by 2020.[9]
• Record earlier budget announcements for ongoing programme funding and expansion in 2012–13, accelerated expansion in 2014–15, and the initial commitment to phase in a nationally coordinated programme in 2005–06, without specifying amounts for those announcements.[6][27]
• Fund the Participant Follow-up Function directly through states and territories under a multilateral National Partnership Agreement within the Federal Financial Relations Framework.[19]
• Support programme expenditure through the Department of Health, including iFOBT screening, advisory and coordination activities, contracted services, communications and follow-up partnership support.[16][17]
• Finance public-hospital colonoscopy and related services through Australian Government funding to states and territories under relevant intergovernmental arrangements.[17]
• Provide Medicare support for relevant consultations, private-sector colonoscopy, histopathology and other private follow-up services; privately treated participants may remain liable for provider gap payments.[10][17]
• Fund Phase Four activities supporting revised guidelines, colonoscopy re-certification, training and a national safety and quality model, although no allocation is specified.[12]
• Fund Menzies School of Health Research to develop and implement the National Indigenous Bowel Screening Pilot in 2018, without specifying the amount.[8]
• Recognise economic modelling that estimated gross costs of 150 million Australian dollars for full biennial screening for people aged 50 to 74, with an estimated undiscounted cost of 25,000 to 41,667 Australian dollars per life-year gained.[25]
• Note modelling that identified advanced bowel cancer treatment costs of more than 100,000 Australian dollars per case and found reviewed screening analyses cost-effective at below 50,000 Australian dollars per life-year gained.[25]
• Maintain the requirement that population screening programmes demonstrate cost-effectiveness across case-finding, diagnosis, treatment and wider healthcare expenditure.[7]
• Recognise participant-paid non-government alternatives, including BowelScreen Australia kits at 39.95 Australian dollars and Rotary Bowelscan kits at approximately 30 Australian dollars, both including pathology services.[26]

No overall Phase Four budget, comprehensive expenditure breakdown, quantified funding gap, resource-mobilisation target or detailed economic assumptions are specified in the supplied material.[14][27]